ABOUT EVENT

What You Missed at the 3rd Molecular Glue Drug Development Summit

This is the only industry-dedicated forum specifically for molecular glues being developed for both degradation and non-degradation throughout the whole development pipeline. Key challenges in rational design, optimal screening strategies, and identifying novel ligases for use with molecular glues were addressed in an intimate setting, driving your discovery engines toward robust clinical candidates and de-risking your development and approval journey.

5 Key Benefits of Attending in 2025

Molecular Glue Drug Development Summit

Streamlined your screening strategies to uncover novel mechanisms of action and enable rational-based glue discovery with insights from Degron Therapeutics, AstraZeneca & Novartis

Molecular Glue Drug Development Summit

Discovered novel small molecule glues by harnessing novel ligases beyond Cereblon and optimizing binders with learning from HB Therapeutics, GSK & Pfizer

Molecular Glue Drug Development Summit

Expanded your lead optimization platforms to develop systematic and rational degrading and non-degrading molecular glues with learnings from Magnet

Molecular Glue Drug Development Summit

Improved pharmacodynamic, toxicology and PKPD properties to streamline discovery and development of safe and effective molecular glues with insights from Asha Therapeutics & Proxygen

Molecular Glue Drug Development Summit

Drove Forward molecular glues from pre-clinical candidates into robust clinical assets with improved efficacy and safety with learnings from Kangpu Biopharmaceuticals & Isoprene Pharmaceuticals

2025 EVENT GUIDE

Here’s What Some of Our Speakers Had to Say About This Meeting:

“This conference provides a robust opportunity to learn from the broader community surrounding current efforts and industry standards in addition to providing a dynamic platform to discuss and present our approaches and novel data.”  

Bradlee Heckmann, Co-Founder & Chief Scientific Officer, Asha Therapeutics

“In the pursuit of developing the next generation of small molecule-based therapeutics, molecular glues hold great promise. I believe that coming together to share strategies, learnings and data will serve to aid our colleagues efforts in the field. Molecular glues offer an area of vast untapped potential. Here, a rising tide will raise all ships”

Jacob Hale, Senior Scientist, Novartis 

“Participating in this meeting allows me to stay updated on the latest breakthroughs in the Target Protein Degradation field. This platform allows me to engage with thought leaders, gain new perspectives, and contribute to shaping the future of therapeutics.”

Julia Dou, Director of Protein Chemistry, Degron Therapeutics

“Small conferences promote 1-1 conversations with other leaders within the MG community with the goal of advancing drug discovery and development.”

Peggy Thompson, Vice President & Head of Biology, Plexium

“The meeting is an outstanding venue for sharing cutting edge ideas by leading academics and industry leaders that is essential for progress in the field.”

Dmitri Ivanov, Associate Professor of Biochemistry and Structural Biology
2025 EVENT GUIDE
REGISTER INTEREST
PARTNER